Xylazine spreads across the US: A growing component of the increasingly synthetic and polysubstance overdose crisis
Joseph S Friedman
1, 2
,
Fernando Montero
3
,
Phillippe Bourgois
4
,
Rafik Wahbi
5
,
Daniel Dye
6
,
David Goodman-Meza
7
,
Chelsea L. Shover
8
Publication type: Journal Article
Publication date: 2022-04-01
scimago Q1
wos Q1
SJR: 1.657
CiteScore: 7.9
Impact factor: 3.6
ISSN: 03768716, 18790046
PubMed ID:
35247724
Pharmacology
Pharmacology (medical)
Psychiatry and Mental health
Toxicology
Abstract
Sharp exacerbations of the US overdose crisis are linked to polysubstance use of synthetic compounds. Xylazine is a veterinary tranquilizer, long noted in the street opioid supply of Puerto Rico, and more recently Philadelphia. Yet its national trends, geographic distribution, and health risks are poorly characterized.In this sequential mixed-methods study, xylazine was increasingly observed by ethnographers in Philadelphia among drug-sellers and people who inject drugs (PWID). Subsequently, we systematically searched for records describing xylazine-present overdose mortality across the US and assessed time trends and overlap with other drugs.In 10 jurisdictions - representing all four US Census Regions - xylazine was increasingly present in overdose deaths, rising from 0.36% of deaths in 015m 6.7% in 2020. The highest xylazine prevalence data was observed in Philadelphia, (25.8% of deaths), followed by Maryland (19.3%) and Connecticut (10.2%). Illicitly-manufactured-fentanyls were present in 98.4% of xylazine-present-overdose-deaths - suggesting a strong ecological link - as well as cocaine (45.4%), benzodiazepines (28.4%), heroin (23.3%), and alcohol (19.7%). PWID in Philadelphia described xylazine as a sought-after adulterant that lengthens the short duration of fentanyl injections. They also linked it to increased risk of soft tissue infection and naloxone-resistant overdose.Xylazine is increasingly present in overdose deaths, linked to the proliferation of illicitly-manufactured-fentanyls. Ethnographic accounts associate it with profound risks for PWID. Nevertheless, many jurisdictions do not routinely test for xylazine, and it is not comprehensively tracked nationally. Further efforts are needed to provide PWID with services that can help minimize additional risks associated with a shifting drug supply.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
5
10
15
20
25
30
|
|
|
International Journal of Drug Policy
26 publications, 9.49%
|
|
|
Journal of Addiction Medicine
17 publications, 6.2%
|
|
|
Harm Reduction Journal
17 publications, 6.2%
|
|
|
Drug and Alcohol Dependence
13 publications, 4.74%
|
|
|
Substance Use and Misuse
9 publications, 3.28%
|
|
|
Drug and Alcohol Dependence Reports
8 publications, 2.92%
|
|
|
Substance Use & Addiction Journal
6 publications, 2.19%
|
|
|
Clinical Toxicology
5 publications, 1.82%
|
|
|
Cureus
4 publications, 1.46%
|
|
|
Addiction
4 publications, 1.46%
|
|
|
JAMA network open
4 publications, 1.46%
|
|
|
Journal of Forensic Sciences
3 publications, 1.09%
|
|
|
Psychopharmacology
3 publications, 1.09%
|
|
|
medRxiv : the preprint server for health sciences
3 publications, 1.09%
|
|
|
American Journal on Addictions
3 publications, 1.09%
|
|
|
International Journal of Environmental Research and Public Health
2 publications, 0.73%
|
|
|
Journal of Hand Surgery
2 publications, 0.73%
|
|
|
Regional Anesthesia and Pain Medicine
2 publications, 0.73%
|
|
|
New England Journal of Medicine
2 publications, 0.73%
|
|
|
Journal of the American Academy of Dermatology
2 publications, 0.73%
|
|
|
Pharmacology Biochemistry and Behavior
2 publications, 0.73%
|
|
|
Neuropsychopharmacology
2 publications, 0.73%
|
|
|
Journal of Analytical Toxicology
2 publications, 0.73%
|
|
|
PLoS ONE
2 publications, 0.73%
|
|
|
Drug Testing and Analysis
2 publications, 0.73%
|
|
|
Journal of Veterinary Emergency and Critical Care
2 publications, 0.73%
|
|
|
Toxics
2 publications, 0.73%
|
|
|
Orthoplastic Surgery
2 publications, 0.73%
|
|
|
American Journal of Drug and Alcohol Abuse
2 publications, 0.73%
|
|
|
5
10
15
20
25
30
|
Publishers
|
10
20
30
40
50
60
70
80
90
|
|
|
Elsevier
82 publications, 29.93%
|
|
|
Springer Nature
35 publications, 12.77%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
29 publications, 10.58%
|
|
|
Wiley
22 publications, 8.03%
|
|
|
Taylor & Francis
20 publications, 7.3%
|
|
|
Cold Spring Harbor Laboratory
15 publications, 5.47%
|
|
|
MDPI
12 publications, 4.38%
|
|
|
SAGE
10 publications, 3.65%
|
|
|
Oxford University Press
6 publications, 2.19%
|
|
|
American Medical Association (AMA)
5 publications, 1.82%
|
|
|
Frontiers Media S.A.
4 publications, 1.46%
|
|
|
Public Library of Science (PLoS)
3 publications, 1.09%
|
|
|
Massachusetts Medical Society
2 publications, 0.73%
|
|
|
American College of Physicians
2 publications, 0.73%
|
|
|
BMJ
2 publications, 0.73%
|
|
|
American Psychiatric Association Publishing
2 publications, 0.73%
|
|
|
American Physiological Society
2 publications, 0.73%
|
|
|
American Chemical Society (ACS)
2 publications, 0.73%
|
|
|
Centers for Disease Control and Prevention (CDC)
2 publications, 0.73%
|
|
|
American Academy of Pediatrics
1 publication, 0.36%
|
|
|
American Public Health Association
1 publication, 0.36%
|
|
|
Society of Forensic Toxicologists
1 publication, 0.36%
|
|
|
SLACK
1 publication, 0.36%
|
|
|
Annual Reviews
1 publication, 0.36%
|
|
|
Royal Society of Chemistry (RSC)
1 publication, 0.36%
|
|
|
Georg Thieme Verlag KG
1 publication, 0.36%
|
|
|
Medknow
1 publication, 0.36%
|
|
|
Walter de Gruyter
1 publication, 0.36%
|
|
|
10
20
30
40
50
60
70
80
90
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
276
Total citations:
276
Citations from 2024:
188
(68.62%)
Cite this
GOST |
RIS |
BibTex
Cite this
GOST
Copy
Friedman J. S. et al. Xylazine spreads across the US: A growing component of the increasingly synthetic and polysubstance overdose crisis // Drug and Alcohol Dependence. 2022. Vol. 233. p. 109380.
GOST all authors (up to 50)
Copy
Friedman J. S., Montero F., Bourgois P., Wahbi R., Dye D., Goodman-Meza D., Shover C. L. Xylazine spreads across the US: A growing component of the increasingly synthetic and polysubstance overdose crisis // Drug and Alcohol Dependence. 2022. Vol. 233. p. 109380.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1016/j.drugalcdep.2022.109380
UR - https://doi.org/10.1016/j.drugalcdep.2022.109380
TI - Xylazine spreads across the US: A growing component of the increasingly synthetic and polysubstance overdose crisis
T2 - Drug and Alcohol Dependence
AU - Friedman, Joseph S
AU - Montero, Fernando
AU - Bourgois, Phillippe
AU - Wahbi, Rafik
AU - Dye, Daniel
AU - Goodman-Meza, David
AU - Shover, Chelsea L.
PY - 2022
DA - 2022/04/01
PB - Elsevier
SP - 109380
VL - 233
PMID - 35247724
SN - 0376-8716
SN - 1879-0046
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2022_Friedman,
author = {Joseph S Friedman and Fernando Montero and Phillippe Bourgois and Rafik Wahbi and Daniel Dye and David Goodman-Meza and Chelsea L. Shover},
title = {Xylazine spreads across the US: A growing component of the increasingly synthetic and polysubstance overdose crisis},
journal = {Drug and Alcohol Dependence},
year = {2022},
volume = {233},
publisher = {Elsevier},
month = {apr},
url = {https://doi.org/10.1016/j.drugalcdep.2022.109380},
pages = {109380},
doi = {10.1016/j.drugalcdep.2022.109380}
}